Transmucosal formulations of levosimendan
US6399610B1 · kind B1 · utility
3Cited by
2References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 31, 2000 |
| Grant date | Jun 4, 2002 |
| Priority date | — |
| Expiry date | Aug 31, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P9/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of administering transmucosally, particularly to oral or nasal mucosa, levosimendan or a pharmaceutically acceptable salt thereof to a patient. The method comprises contacting an intact mucous membrane with a source of levosimendan, and maintaining said source with said mucous membrane for a sufficient time period to deliver levosimendan to the patient. Transmucosal preparations of levosimendan are also described. Levosimendan is useful in the treatment of heart failure.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.